I certainly don't know what's going on, but I think that calling this a "Zertane disappointment" may be somewhat premature. Of course we all wanted to see an announcement of a deal on Zertane immediately following the POPE approval, and we all want to have weekly updates from the company on the status thereof. However, I am not that 'disappointed' that we haven't heard anything yet. these kinds of deals are not simple, and there is much posturing throughout, especially if there is the prospect of more than one player involved.
With the company having already disclosed that they are in negotiations, it is incumbent upon them to advise of any change in that status - i.e.: no deal being negotiated any longer. Maybe the company is being "secretive and sneaky" as you say. However, I can understand the secrecy, and the sneakiness, to some extent, if it is in pursuit of the best deal possible and related to dealings with prospective acquirers/partners. If there is no deal then the company may have some issues with respect to being secretive and sneaky with investors/shareholders. that would be a whole different story.
To this point, management has not done anything that would reflect deception as a typical course of dealing. That's not to say there is none, but it all comes out in the wash eventually, and management has not sold a single share of stock and is in the same boat as we are.
If the drugs are good, the rewards will be there. Patience.
AMPE doesn't want to conduct the Phase 3 themselves. They want a partner to pay for & conduct it as part of some deal involving an upfront payment & royalties on future sales. Problem is, they haven't been able to find a willing partner. Or maybe more likely, at a price they find acceptable.